A P S Hungin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10382845/publications.pdf

Version: 2024-02-01

361413 552781 3,442 26 20 26 citations h-index g-index papers 26 26 26 3321 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Current concepts in the management of <i>Helicobacter pylori</i> infectionâ€"The Maastricht 2â€2000 Consensus Report. Alimentary Pharmacology and Therapeutics, 2002, 16, 167-180.	3.7	1,068
2	The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40â€∫000 subjects. Alimentary Pharmacology and Therapeutics, 2003, 17, 643-650.	3.7	654
3	Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Alimentary Pharmacology and Therapeutics, 2005, 21, 1365-1375.	3.7	413
4	Inflammatory bowel disease: epidemiology and management in an English general practice population. Alimentary Pharmacology and Therapeutics, 2000, 14, 1553-1559.	3.7	252
5	Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide. Alimentary Pharmacology and Therapeutics, 2013, 38, 864-886.	3.7	168
6	The Fight for â€~Health-related Normality': A Qualitative Study of the Experiences of Individuals Living with Established Inflammatory Bowel Disease (IBD). Journal of Health Psychology, 2005, 10, 443-455.	2.3	107
7	Systematic review: probiotics in the management of lower gastrointestinal symptoms – an updated evidenceâ€based international consensus. Alimentary Pharmacology and Therapeutics, 2018, 47, 1054-1070.	3.7	101
8	World Gastroenterology Organisation Global Guidelines Irritable Bowel Syndrome. Journal of Clinical Gastroenterology, 2016, 50, 704-713.	2.2	90
9	Quality of life in patients with established inflammatory bowel disease: a UK general practice survey. Alimentary Pharmacology and Therapeutics, 2004, 19, 529-535.	3.7	77
10	The effect of <scp>Helicobacter pylori</scp> and its eradication on gastroâ€oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. Alimentary Pharmacology and Therapeutics, 2004, 20, 733-744.	3.7	68
11	Systematic review: frequency and reasons for consultation for gastroâ€oesophageal reflux disease and dyspepsia. Alimentary Pharmacology and Therapeutics, 2009, 30, 331-342.	3.7	60
12	Review article: quality-of-life issues in gastro-oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 2005, 22, 41-47.	3.7	45
13	Patients' explanatory models for irritable bowel syndrome: symptoms and treatment more important than explaining aetiology. Family Practice, 2008, 26, 40-47.	1.9	45
14	Medication beliefs among patients with inflammatory bowel disease who report low quality of life: a qualitative study. BMC Gastroenterology, 2007, 7, 20.	2.0	44
15	Systematic review: the perceptions, diagnosis and management of irritable bowel syndrome in primary care - A Rome Foundation Working Team Report. Alimentary Pharmacology and Therapeutics, 2014, 40, 1133-1145.	3.7	40
16	GPs' explanatory models for irritable bowel syndrome: a mismatch with patient models?. Family Practice, 2008, 26, 34-39.	1.9	33
17	Review article: gastroâ€oesophageal reflux disease – the health economic implications. Alimentary Pharmacology and Therapeutics, 2005, 22, 20-31.	3.7	32
18	Long-term aminosalicylate therapy is under-used in patients with ulcerative colitis: a cross-sectional survey. Alimentary Pharmacology and Therapeutics, 2002, 16, 1889-1893.	3.7	30

A P S Hungin

#	Article	IF	CITATION
19	Symptoms in patients on longâ€term proton pump inhibitors: prevalence and predictors. Alimentary Pharmacology and Therapeutics, 2009, 29, 431-439.	3.7	28
20	Irritable bowel syndrome: an integrated explanatory model for clinical practice. Neurogastroenterology and Motility, 2015, 27, 750-763.	3.0	22
21	Use of Proton Pump Inhibitors: An Exploration of the Attitudes, Knowledge and Perceptions of General Practitioners. Digestion, 2005, 72, 212-218.	2.3	20
22	Helicobacter pylori eradication in longâ€term proton pump inhibitor users in primary care: a randomizedâ€controlled trial. Alimentary Pharmacology and Therapeutics, 2007, 25, 585-592.	3.7	14
23	Self-help interventions in irritable bowel syndrome. Gut, 2006, 55, 603-604.	12.1	10
24	<i>Helicobacter pylori</i> eradication in longâ€term proton pump inhibitor users is highly costâ€effective: economic analysis of the HELPUP trial. Alimentary Pharmacology and Therapeutics, 2008, 28, 1297-1303.	3.7	10
25	Prevalence, symptom patterns and management of episodic diarrhoea in the community: a populationâ€based survey in 11 countries. Alimentary Pharmacology and Therapeutics, 2016, 43, 586-595.	3.7	9
26	Dyspepsia: gaps between primary and secondary care. Digestive and Liver Disease, 2002, 34, 243-245.	0.9	2